DMTK vs. XGN, RNLX, PMD, BGLC, OPGN, FRES, ACON, NVTA, CNTG, and ENZ
Should you be buying DermTech stock or one of its competitors? The main competitors of DermTech include Exagen (XGN), Renalytix (RNLX), Psychemedics (PMD), BioNexus Gene Lab (BGLC), OpGen (OPGN), Fresh2 Group (FRES), Aclarion (ACON), Invitae (NVTA), Centogene (CNTG), and Enzo Biochem (ENZ). These companies are all part of the "medical laboratories" industry.
Exagen (NASDAQ:XGN) and DermTech (NASDAQ:DMTK) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, community ranking, profitability, earnings, dividends, media sentiment, valuation, risk and institutional ownership.
Exagen has a net margin of -34.74% compared to Exagen's net margin of -572.19%. DermTech's return on equity of -75.86% beat Exagen's return on equity.
DermTech received 26 more outperform votes than Exagen when rated by MarketBeat users. Likewise, 57.50% of users gave DermTech an outperform vote while only 54.05% of users gave Exagen an outperform vote.
Exagen has higher revenue and earnings than DermTech. Exagen is trading at a lower price-to-earnings ratio than DermTech, indicating that it is currently the more affordable of the two stocks.
Exagen has a beta of 1.2, meaning that its share price is 20% more volatile than the S&P 500. Comparatively, DermTech has a beta of 2.53, meaning that its share price is 153% more volatile than the S&P 500.
In the previous week, Exagen and Exagen both had 2 articles in the media. Exagen's average media sentiment score of 1.19 beat DermTech's score of 0.92 indicating that DermTech is being referred to more favorably in the news media.
75.3% of Exagen shares are held by institutional investors. Comparatively, 20.5% of DermTech shares are held by institutional investors. 26.1% of Exagen shares are held by company insiders. Comparatively, 5.1% of DermTech shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Exagen presently has a consensus target price of $7.00, indicating a potential upside of 258.97%. DermTech has a consensus target price of $2.38, indicating a potential upside of 653.54%. Given Exagen's higher possible upside, analysts plainly believe DermTech is more favorable than Exagen.
Summary
Exagen beats DermTech on 10 of the 17 factors compared between the two stocks.
Get DermTech News Delivered to You Automatically
Sign up to receive the latest news and ratings for DMTK and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding DMTK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
DermTech Competitors List
Related Companies and Tools
